Efficacy & Safety Assessment of Beltavac® With Polymerized Extract of HDM

See also
Status	Clinical Trial	Phase
Completed	`NCT02443805` - Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR	Phase 3
Completed	`NCT03094845` - Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients	Phase 2
Completed	`NCT01930461` - Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma	Phase 2
Completed	`NCT01923792` - ToleroMune House Dust Mite Follow on Study	N/A
Completed	`NCT00574704` - A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis	Phase 2
Completed	`NCT00263549` - Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis	Phase 4
Completed	`NCT05019209` - Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients	N/A
Recruiting	`NCT02238353` - AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)	Phase 4
Completed	`NCT01454544` - A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet	Phase 3
Terminated	`NCT01777464` - Role of the Central Nervous System in Allergic Rhinitis	N/A
Completed	`NCT00574223` - A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis	Phase 2
Completed	`NCT02345278` - SUBLIVAC FIX Mite Mixture Dose Tolerability Study	Phase 1/Phase 2
Completed	`NCT01608243` - Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts	Phase 1
Completed	`NCT04435678` - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens	N/A
Completed	`NCT01134757` - Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction.	N/A
Not yet recruiting	`NCT05400811` - Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis	Phase 3
Not yet recruiting	`NCT05450289` - The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving Immunotherapy	N/A
Recruiting	`NCT05174689` - Epigenetic Regulation of Exercise Induced Asthma	N/A
Terminated	`NCT04874714` - Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis	Phase 3
Completed	`NCT00380926` - Fish Oil and Asthma in House Dust Mite Allergy	Phase 2/Phase 3

NCT number	NCT05395689
Study type	Interventional
Source	Probelte Pharma S.L.U.
Contact	Inma Buendia
Phone	+34 608 933 618
Email	inmaculadabuendia@probeltepharma.es
Status	Recruiting
Phase	Phase 3
Start date	January 17, 2022
Completion date	February 2024

Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM — PROACAROS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms